gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

CD6 molecule

CD6, T-12
This gene encodes a protein found on the outer membrane of T-lymphocytes as well as some other immune cells. The encoded protein contains three scavenger receptor cysteine-rich (SRCR) domains and a binding site for an activated leukocyte cell adhesion molecule. The gene product is important for continuation of T cell activation. This gene may be associated with susceptibility to multiple sclerosis (PMID: 19525953, 21849685). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2011] (from NCBI)
Top mentioned proteins: CD5, CD4, CD8, CD2, CD166
Papers on CD6
Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.
Mazorra et al., Havana, Cuba. In Mabs, Feb 2016
Itolizumab, a monoclonal antibody specific for the human CD6 molecule mainly expressed on T lymphocytes, has been shown to inhibit proliferation of T cells and proinflammatory cytokine production in psoriasis patients.
Molecular survey of Enterocytozoon bieneusi in sheep and goats in China.
Ning et al., Zhengzhou, China. In Parasit Vectors, Dec 2015
A further four known genotypes (CD6, COS-I, BEB6, and J) and 22 novel genotypes (CHG1-CHG3, CHG5, CHG8, CHG10-CHG14, CHG16-CHG18, CHG20, CHG22, CHG24, CHS3, CHS4 and CHS6-CHS9) formed a clade within the group 2. One novel genotype (CHG21) was clustered in the group 9 with the genotype CM4.
CD6 as a cell surface receptor and as a target for regulating immune responses.
Brown, Oxford, United Kingdom. In Curr Drug Targets, Sep 2015
UNASSIGNED: CD6 has been exploited as a drug target as its expression is restricted, primarily to T cells, it has a well characterised cell surface ligand, CD166 and regulates T cell activation through a long cytoplasmic tail.
Tuning T cell activation: the function of CD6 at the immunological synapse and in T cell responses.
Carmo et al., Porto, Portugal. In Curr Drug Targets, Jul 2015
UNASSIGNED: CD6 immunotherapy to treat psoriasis and rheumatoid arthritis has reached the clinical trial stage with apparent success, and targeting CD6 with mAbs is being used in several animal models of autoimmunity and neuroinflammation with promising indications.
Pattern Recognition by CD6: a Scavenger-Like Lymphocyte Receptor.
Lozano et al., Barcelona, Spain. In Curr Drug Targets, Apr 2015
UNASSIGNED: CD6, one of the first antigens to be identified on T cells, is a membrane glycoprotein that physically associates with the antigen receptor complex.
A Computational Gene Expression Score for Predicting Immune Injury in Renal Allografts.
Sarwal et al., San Francisco, United States. In Plos One, 2014
RESULTS: The 11 gene qPCR based tissue CRM score (tCRM) was significantly increased in AR (5.68 ± 0.91) when compared to STA (1.29 ± 0.28; p < 0.001) and pIFTA (7.94 ± 2.278 versus 2.28 ± 0.66; p = 0.04), with greatest significance for CXCL9 and CXCL10 in AR (p <0.001) and CD6 (p<0.01),
Functionalization of Cyclodextrins with N-Hydroxyphthalimide Moiety: A New Class of Supramolecular Pro-Oxidant Organocatalysts.
Punta et al., Milano, Italy. In Molecules, 2014
This work reports the synthesis of two β-cyclodextrin derivatives (CD5 and CD6) having a different degree of methylation and bearing a NHPI moiety.
Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.
David et al., Pondicherry, India. In Clin Cosmet Investig Dermatol, 2014
Itolizumab, a humanized anti-CD6 monoclonal antibody, is a new molecule that acts by immunomodulating the CD6 molecule.
[What's new in dermatological therapy?].
Meunier, Nîmes, France. In Ann Dermatol Venereol, 2014
The vast majority of them were dedicated to the treatment of psoriasis (anti-TNF, ustekinumab, antibodies against IL-17 or its receptors, anti-IL-23, anti-CD6 and ponesimod).
Human Gene Expression in Uncomplicated Plasmodium falciparum Malaria.
Krogstad et al., New Orleans, United States. In J Immunol Res, 2014
In contrast, the expression of immune-modulatory (transcription factor 7, HLV-DOA, and CD6) and apoptosis inhibitory (c-myc, caspase 8, and Fas Ligand G) genes was downregulated initially and returned to normal with clinical recovery (days 7-10).
Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.
Wan et al., Silver Spring, United States. In J Virol, 2014
In the present study, we evaluated the in vitro and in vivo efficacies of four monoclonal antibodies (MAbs): HF5 and CD6, which are specific to two different epitopes in the NA of 2009 pandemic H1N1 (pH1N1) virus, and 4E9 and 1H5, which are specific to a conserved epitope in the NA of both H1N1 and H5N1 viruses.
Quantitative proteomics analysis of signalosome dynamics in primary T cells identifies the surface receptor CD6 as a Lat adaptor-independent TCR signaling hub.
Malissen et al., Marseille, France. In Nat Immunol, 2014
The surface receptor CD6 was able to initiate its own signaling pathway by recruiting SLP-76 and the guanine nucleotide-exchange factor Vav1 regardless of the presence of Lat.
CD6 attenuates early and late signaling events, setting thresholds for T-cell activation.
Carmo et al., Porto, Portugal. In Eur J Immunol, 2012
CD6 is a signaling attenuator whose expression alone, i.e. in the absence of ligand engagement, is sufficient to restrain signaling in T cells.
The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation.
Hafler et al., New Haven, United States. In J Immunol, 2011
These findings indicate that the multiple sclerosis risk allele in the CD6 locus is associated with altered proliferation of CD4(+) T cells
Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome.
Renaudineau et al., Brest, France. In J Autoimmun, 2010
CD6+ B cells are diminished in Sjogren's syndrome
The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion.
Falk et al., Stockholm, Sweden. In J Innate Immun, 2010
CD6 expression on peripheral NK cells marks a novel CD56(dim) subpopulation associated with distinct patterns of cytokine and chemokine secretion.
The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study.
International Multiple Sclerosis Genetics Consortium, In Plos One, 2010
association of single nucleotide polymorphisms to multiple sclerosis
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
Oksenberg et al., Boston, United States. In Nat Genet, 2009
Replication in an independent set of 2,215 subjects with multiple sclerosis (MS) and 2,116 control subjects validates new MS susceptibility loci at TNFRSF1A, IRF8 and CD6; TNFRSF1A harbors two independent susceptibility alleles.
Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system.
Prat et al., Montréal, Canada. In Nat Immunol, 2008
ALCAM expressed on BBB endothelium localized together with CD6 on leukocytes and with BBB endothelium transmigratory cups.
Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Gonin et al., Boston, United States. In J Clin Oncol, 1992
In this study, we have evaluated the clinical effects of selective in vitro T-cell depletion of donor allogeneic bone marrow by using a single monoclonal antibody ([MoAb] anti-T12, CD6) and rabbit complement.
share on facebooktweetadd +1mail to friends